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A dipstick assay for the detection of brucella-specific immunoglobulin M antibodies was evaluated with 707
sera from 247 laboratory-confirmed brucellosis patients and 342 control sera from brucellosis-free individuals.
These sera were collected from six different countries. The assay was found to be highly sensitive and specific.
In addition, the test is easy to use and does not require specialized training or equipment, and the components
are stable without a requirement for refrigeration. All of these factors make the test ideal for developing
countries and rural settings.
Brucellosis is an important but often neglected cause of
morbidity in many regions of the world (1, 2, 4, 9, 17, 19, 25).
The disease is most common in rural areas and among those
involved in animal husbandry. Brucellosis also occurs in urban
settings when animals are kept in compounds around houses
and among meat-packers, dairy workers, and veterinarians.
Brucella abortus, Brucella suis, and Brucella melitensis are the
causative agents, which have, respectively, cattle, swine, and
goats and sheep as their main hosts. The disease is transmitted
from infected animals by direct contact with blood, fetuses and
fetal membranes, uterine secretions, and aborted material or
through consumption of infected, raw animal products, of
which milk and milk products are the most important (26).
The treatment of chronic brucellosis is complicated and re-
quires prolonged medication compared to that for acute bru-
cellosis; the disease should be diagnosed and treated promptly.
Typical severe acute brucellosis in its early stages cannot be
diagnosed on clinical grounds along (11). Symptoms and signs
are nonspecific, and several other febrile illnesses may be sim-
ulated, as for example glandular fever, influenza, malaria, and
enteric infections. Also, when an unusual complication is
present, brucellosis may be overlooked. Laboratory tests such
as culture and serological tests including the serum agglutina-
tion test (SAT) (7, 24), the anti-human globulin test (Coombs
test) (21), the complement fixation test (12), and enzyme-
linked immunosorbent assay (ELISA) (5, 13, 20), therefore,
are indispensable for an accurate diagnosis.
The detection of Brucella-specific immunoglobulin M (IgM)
antibodies allows the diagnosis of patients with brucellosis at
an early stage or acute disease and also may help to discrimi-
nate between patients in the early phase of brucellosis and
those with chronic brucellosis. In countries where the disease is
highly endemic, a large proportion of the population may have
persistent Brucella-specific IgG antibodies. Under such condi-
tions, the detection of specific IgM antibodies is important to
make the laboratory diagnosis of brucellosis in the early phase
of the disease. Specific IgM antibodies can be detected by SAT
performed in the presence of either 2-mercaptoethanol (2-ME
test) or dithiothreitol (SAT-DTT) (3, 10, 18, 22) and by ELISA
(5, 13, 20). The SATs and ELISA can be performed only by
relatively skilled personnel in well-equipped laboratories, and
these tests are too elaborate for widespread application under
field conditions. In situations where appropriate diagnostic
facilities are lacking, a colorimetric test, with a simplified for-
mat, giving a positive or negative result could serve as a con-
firmatory test for human brucellosis in the acute phase of the
disease. For this reason, we developed a simple dipstick assay
for the detection of Brucella-specific IgM antibodies in human
serum samples, which is evaluated in this paper.
The dipstick heat-resistant antigen was prepared from a
liquid culture of B. abortus 1119-2 by heating washed cells at
95°C followed by removal of cell debris by centrifugation, and
this preparation was then applied as a distinct line to a nitro-
cellulose strip (16). To obtain an internal control, an anti-
human IgM antibody was applied as a coating to the nitrocel-
lulose as a separate line (16). The coated strips were blocked
with skimmed milk and dried, made to adhere to a plastic
backing with double-sided tape, cut into 2.5-mm-wide sticks,
and shipped with a vial of wetting agent. A nonenzymatic
detection reagent was prepared by conjugation of a monoclo-
nal anti-human IgM antibody to colloidal dye particles (palanyl
red) according to a patented method (14, 15, 23). To increase
stability, the stained antibody suspension was lyophilized and
shipped with a rehydration reagent in a separate bottle (16).
The dipstick assay is performed by incubation for 3 h of a
wetted dipstick in 250 ml of reconstituted detection reagent
mixed with 5 ml of a serum sample. At the end of the incuba-
tion period, the dipstick is thoroughly rinsed with tap water in
order to remove excess detection reagent and air dried at
* Corresponding author. Mailing address: Department of Biomedi-
cal Research, Royal Tropical Institute, Meibergdreef 39, 1105 AZ
Amsterdam, The Netherlands. Phone: 31-20-5665470. Fax: 31-20-
6971841. E-mail: H.Smits@kit.nl.
4179
ambient temperature. A reddish-stained antigen band indi-
cates a positive reaction. The staining of the antigen band can
be scored as 11 through 41 by comparison with a colored
reference strip; when no coloring is observed, the test is neg-
ative. In order to assess the clinical utility of the assay, labo-
ratories in Portugal, Russia, Spain, The Netherlands, and the
United States were provided with dipsticks, test reagents, and
test tubes and were asked to perform the assay according to an
accompanying protocol. In the laboratories in Portugal, Rus-
sia, Spain, and The Netherlands, randomly selected serum
samples from laboratory-confirmed brucellosis patients and
brucellosis-free individuals were tested in order to determine
the sensitivity and specificity of the assay at different stages of
the disease and the results of these studies were combined.
Furthermore, samples from an outbreak of brucellosis were
tested in the United States, and in Yemen, a group of samples
from culture-proven patients was tested.
The first study group of 150 patients included 39 patients
with 71 samples from Portugal, 90 patients from Russia, 19
patients with 49 samples from Spain, and 2 patients from The
Netherlands. Patients were considered laboratory-confirmed
brucellosis patients based on the results of culture, SAT, and
Coombs test. Thirty-nine (26%) patients had positive blood
cultures, 38 of which were positive for B. melitensis and 1 of
which was positive for B. suis. The control group (342 samples)
included 94 patients with clinical suspicion of brucellosis but
negative results in the Rose Bengal test. The remaining mem-
bers of the control group were patients with the following
conditions (number of patients): autoimmune disease (28),
bartonellosis (Bartonella henselae) (2), hantavirus infection
(11), hepatitis A (5), hepatitis B (7), human immunodeficiency
virus infection (20), legionellosis (11), leptospirosis (8), Lyme
borreliosis (20), malaria (20), meningitis (7), meningococcal
meningitis (8), Mycoplasma pneumoniae infection (7),
ochrobacteriosis (2), syphilis (20), toxoplasmosis (9), tularemia
(Francisella tularensis) (12), Yersinia pseudotuberculosis II in-
fection (1), Yersinia enterocolitica 03 infection (1), and Y. en-
terocolitica 09 infection (4). Forty-five serum samples from
healthy donors were also included.
To calculate the sensitivity of the dipstick assay at different
stages of brucellosis, the serum samples from the patients were
stratified according to the duration of the disease: 73 samples
collected within 2 months, 77 samples for the period of 2 to 4
months, 52 samples for the period of 4 to 6 months and 77
samples collected after .6 months of treatment (Table 1). The
sensitivity of the dipstick assay was 89.0% for the samples
collected within 2 months after the onset of the disease and
83.1% for the samples collected 2 to 4 months after the onset
of the disease (Table 2). The sensitivity dropped to 32.6 and
29.8% for the two groups of samples collected after 4 and 6
months of treatment, respectively (Table 2). Furthermore, the
staining intensity of the antigen band of the dipstick was mod-
erate (21) to strong (41) for most of the positive samples
collected early in the disease (Table 1). The percentages of the
four groups that stained as .11 declined with the duration of
treatment: 82.2, 58.4, 17.3, and 10.3%, respectively (Table 1).
Compared with that of the SAT, the sensitivity of the dipstick
assay was higher for the samples collected during the first 4
months of the disease but lower for the samples collected after
the fourth month (Table 2). The sensitivity of the dipstick assay
for the samples collected during the first 4 months also was
higher than or equal to that of the Coombs test (Table 2). The
sensitivity of the dipstick assay was higher than the sensitivity
of the SAT performed in the presence of reducing agent, an
assay often used to assess the presence of specific IgM anti-
bodies, for all four groups of samples. The difference in sen-
sitivity between these two assays was largest for the samples
collected 2 to 4 months after the onset of the disease. Samples
collected from 5 of 89 patients during the first 6 months of the
disease were negative in the dipstick assay. These samples were
also negative in the 2-ME test. The clinical symptoms of these
five patients were consistent with chronic brucellosis rather
than acute or recent-onset brucellosis; the final diagnosis was
Brucella arthritis, spondylitis, and neurobrucellosis for one pa-
tient each, and Brucella was isolated from bone marrow from
two patients. Only 4 of 297 samples from the noncase patients
gave a positive result in the dipstick assay, giving a specificity of
98.6%. These four patients included one suspected brucellosis
patient with a negative result in the Rose Bengal test, one
patient with syphilis, and two patients with yersiniosis. The
staining intensity of all four samples was rated 21. None of the
45 blood bank sera gave a positive result.
Of the case patients from Portugal, Russia, and Spain, 39
patients had a positive blood culture. Serum samples from 36
(92.3%) of these 39 blood culture-positive patients gave a
positive result in the dipstick assay. Of the patients with a
positive result in the dipstick assay, one was culture positive for
B. suis and the others were positive for B. melitensis. To dem-
onstrate the reactivity of the dipstick for patients infected with
B. abortus, a group of single serum samples from 60 culture-
proven patients from Yemen was tested. Of these patients, 42
had a positive culture for B. abortus and 18 were positive for B.
melitensis. The sensitivity of the dipstick assay for these two
groups of patients was 95.2 and 83.3%, respectively. The ma-
jority (53 and 80%, respectively) of the dipstick-positive sam-
TABLE 1. Staining intensity of dipstick assay for samples collected
at different stages of the disease
Staining intensity
of dipstick assay
No. of samples with indicated staining intensity
at mo after onset of disease:
0–2 2–4 4–6 .6
Negative 8 13 35 54
11 5 19 8 15
21 17 14 7 5
31 16 15 1 3
41 27 16 1
Total 73 77 52 77
TABLE 2. Sensitivity of dipstick assay and other serological tests in
relation to duration of the disease
Testa
Sensitivity (%) at mo after onset of disease:
0–2 2–4 4–6 .6
Dipstick assay 89.0 83.1 32.6 29.8
SAT 79.5 64.4 76.9 50.6
SAT-DTT and 2-MEb 67.1 19.1 13.5 6.0
Coombs test 39.7 88.1 92.3 81.8
a The dipstick assay was considered positive when a staining intensity of .11
was observed. The SAT was considered positive when a titer of $1:160 was
obtained. The 2-ME test and the SAT-DTT were considered positive when a
$4-fold reduction in titer compared with that of the SAT was observed. The
Coombs test was considered positive when a $4-fold increase in titer was mea-
sured.
b The SAT-DTT was performed on the samples from Spain. The 2-ME test
was performed on the samples from Portugal. The SAT-DTT or the 2-ME test
was not done for the samples from Russia and The Netherlands.
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ples of these two groups gave a moderate to strong staining
intensity.
To validate the dipstick assay further and to test the reac-
tivity of the dipstick assay for patients with a B. suis infection,
the assay was applied on 93 paired serum samples derived from
37 laboratory-confirmed brucellosis patients infected with B.
suis during a localized outbreak in a slaughterhouse in the
United States during 1976. All initial serum samples tested
positive in the dipstick, giving a sensitivity of 100% (Table 3).
Of the samples taken 12 months on average after the first
sample, 61% still tested positive, but while the staining inten-
sity of the initial samples was $21 for all but one sample, most
of the subsequent samples gave a 11 staining intensity.
The results of the present study show that the dipstick assay
is highly sensitive and specific for the serodiagnosis of human
brucellosis in the early phase of the disease. For the combined
group of samples from Portugal, Russia, Spain, and The Neth-
erlands, the sensitivity was 89.0% for samples collected during
the first 2 months of the disease and 83.1% for samples col-
lected 2 to 4 months after the onset of the disease. The sensi-
tivity for the group of samples from the United States collected
early in the disease during an outbreak of brucellosis was even
higher (100%). Infection with B. melitensis was the most com-
mon cause of disease among the first study group. All patients
in the outbreak were infected with B. suis. The somewhat lower
sensitivity of the dipstick assay calculated for the results of the
first study, however, most likely was not related to the differ-
ence in causative agent. Some of the patients with a negative
result in the dipstick assay from the first study group likely
suffered from chronic disease despite the reported recent onset
of the disease, and this may well have accounted for the lower
sensitivity. The dipstick assay performed equally well for the
confirmation of suspected brucellosis patients with B. abortus,
B. melitensis, or B. suis infections. The sensitivity was high
irrespective of whether it was calculated based on the results
obtained for patients confirmed by serological methods or by
culture. The sensitivity was 93.5% when only blood culture-
proven brucellosis patients were considered.
The specificity of the dipstick assay was calculated to be
98.6%. The selectivity for sera of patients with Y. enterocolitica
or cholera infection needs further investigation, as these or-
ganisms share antigenic structures with brucellas (6, 8). How-
ever, the symptoms of patients with yersiniosis or cholera are
distinct from those of patients with brucellosis.
The high sensitivity and specificity of the dipstick assay for
samples collected in the acute phase of the disease demon-
strated that the assay is highly suitable for use in serodiagnosis
of patients with acute disease. Compared with SAT-DTT or
the 2-ME test, the dipstick assay has a higher sensitivity and is
easier to use: the dipstick assay requires only a few minutes of
handling time to perform, does not need special equipment or
electricity, and can be performed by modestly trained person-
nel with a minimum of instructions. The dipstick assay also is
easier to apply than ELISA. The dipstick assay is suited for use
in the field and in laboratories that are not equipped to per-
form the more complicated tests. The assay also has potential
to replace the other methods for distinguishing patients with
acute brucellosis from those with a chronic infection or with
persisting IgG antibodies due to a previous infection. It may be
noted, though, that consistent with the results of ELISA (7, 11)
our results show that specific IgM antibodies may remain de-
tectable for several months and sometimes even much longer
after the onset of the disease. However, while most serum
samples collected early in the disease gave a $21 staining,
most of the sera collected later, 4 to 6 months after treatment
had been initiated, tested as 11.
The five laboratories participating in the study found the test
easy to perform and were satisfied with the result. It was also
noted that the development of color on the dipstick could be
maintained as a permanent record in a folder or attached to
the patient record.
In conclusion, the dipstick assay described here is an easy-
to-perform method for the quick serodiagnosis of acute human
brucellosis. Due to its robustness and simplicity, the assay is
highly suitable for application under field conditions. Ideally,
application of two dipsticks, one for the detection of specific
IgM antibodies and another for the detection of specific IgG
antibodies, would be needed to cover the possibility of both
acute or recent and chronic brucellosis. The development of an
IgG-specific rapid test for brucellosis is now in progress. A
further prospective study will be required to demonstrate the
clinical utility of the assay and to calculate the sensitivity,
specificity, and predictive value for patients living in an area
where brucellosis is endemic.
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